TY - JOUR
T1 - Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis
AU - Muro, Yoshinao
AU - Sugiura, Kazumitsu
AU - Akiyama, Masashi
N1 - Funding Information:
Acknowledgments This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (23591618 to YM and 23249058 to MA) and by a grant from the Ministry of Health, Labour and Welfare of Japan (to YM).
PY - 2013/3
Y1 - 2013/3
N2 - Autoantibodies against melanoma differentiation-associated gene 5 (MDA5) are important serological markers in dermatomyositis (DM) with rapidly progressive interstitial lung disease (ILD). Recent studies noted that anti-MDA5 antibody (anti-MDA5ab), ferritin, and IL-18 are useful biomarkers for evaluating the responses to treatment and the status of ILD in anti-MDA5ab-positive DM. In this study, we further studied the importance of anti-MDA5ab levels and of ferritin and IL-18 concentrations in our patients. These biomarkers could be sometimes useful for evaluating ILD status and/or predicting the prognosis in patients with anti-MDA5ab-positive DM with several exceptional cases. A single-point evaluation of anti-MDA5ab levels and of ferritin and IL-18 concentrations has limitations in predicting the prognosis of ILD with DM. We consider that the timing of initial therapy and the anti-MDA5ab isotype, in addition to the patient's age, are also crucial factors for predicting the prognosis.
AB - Autoantibodies against melanoma differentiation-associated gene 5 (MDA5) are important serological markers in dermatomyositis (DM) with rapidly progressive interstitial lung disease (ILD). Recent studies noted that anti-MDA5 antibody (anti-MDA5ab), ferritin, and IL-18 are useful biomarkers for evaluating the responses to treatment and the status of ILD in anti-MDA5ab-positive DM. In this study, we further studied the importance of anti-MDA5ab levels and of ferritin and IL-18 concentrations in our patients. These biomarkers could be sometimes useful for evaluating ILD status and/or predicting the prognosis in patients with anti-MDA5ab-positive DM with several exceptional cases. A single-point evaluation of anti-MDA5ab levels and of ferritin and IL-18 concentrations has limitations in predicting the prognosis of ILD with DM. We consider that the timing of initial therapy and the anti-MDA5ab isotype, in addition to the patient's age, are also crucial factors for predicting the prognosis.
UR - http://www.scopus.com/inward/record.url?scp=84876686862&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876686862&partnerID=8YFLogxK
U2 - 10.1007/s10067-012-2142-x
DO - 10.1007/s10067-012-2142-x
M3 - Article
C2 - 23250474
AN - SCOPUS:84876686862
SN - 0770-3198
VL - 32
SP - 395
EP - 398
JO - Clinical Rheumatology
JF - Clinical Rheumatology
IS - 3
ER -